Qi-Jing’s early research at Stanford focused on TCR antigen recognition and signaling sensitivity. He made a series of key contributions in defining the minimal subunit, rate-limiting step, and sensitivity controls of TCR activation. In 2008, he established his own lab at Duke University, expanding into cancer immunology and clinical immunotherapy. In 2022, he joined A*STAR Singapore as a Distinguished Principal Scientist at IMCB and SIgN. Beyond basic research, Qi-Jing has been continuously translating his expertise in molecular biology and T cell biology into cancer immunotherapy and clinical immune monitoring. As an applied immunologist, he has built immunogenomics profiling tools, developed AI-driven antigen-specific TCR discovery platforms, engineered T cell and NK cell-based therapeutics, and designed and aided more than twenty phase I/II therapeutical trials against various cancers. As a serial entrepreneur, he co-founded three clinical-stage companies advancing CAR-T, TCR-T, and TIL cell therapeutics.